170 related articles for article (PubMed ID: 34906550)
1. Advances in therapeutic and vaccine targets for Cryptosporidium: Challenges and possible mitigation strategies.
Rahman SU; Mi R; Zhou S; Gong H; Ullah M; Huang Y; Han X; Chen Z
Acta Trop; 2022 Feb; 226():106273. PubMed ID: 34906550
[TBL] [Abstract][Full Text] [Related]
2. Cryptosporidiosis Drug Discovery: Opportunities and Challenges.
Manjunatha UH; Chao AT; Leong FJ; Diagana TT
ACS Infect Dis; 2016 Aug; 2(8):530-7. PubMed ID: 27626293
[TBL] [Abstract][Full Text] [Related]
3. Treatment of cryptosporidiosis: nitazoxanide yes, but we can do better.
Caravedo MA; White AC
Expert Rev Anti Infect Ther; 2023 Feb; 21(2):167-173. PubMed ID: 36533398
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis.
Zhang CX; Love MS; McNamara CW; Chi V; Woods AK; Joseph S; Schaefer DA; Betzer DP; Riggs MW; Iroh Tam PY; Van Voorhis WC; Arnold SLM
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0156021. PubMed ID: 34748385
[TBL] [Abstract][Full Text] [Related]
5. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium.
Checkley W; White AC; Jaganath D; Arrowood MJ; Chalmers RM; Chen XM; Fayer R; Griffiths JK; Guerrant RL; Hedstrom L; Huston CD; Kotloff KL; Kang G; Mead JR; Miller M; Petri WA; Priest JW; Roos DS; Striepen B; Thompson RC; Ward HD; Van Voorhis WA; Xiao L; Zhu G; Houpt ER
Lancet Infect Dis; 2015 Jan; 15(1):85-94. PubMed ID: 25278220
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic screening techniques for
Love MS; McNamara CW
Expert Opin Drug Discov; 2021 Jan; 16(1):59-74. PubMed ID: 32892652
[No Abstract] [Full Text] [Related]
7. Novel treatment strategies and drugs in development for cryptosporidiosis.
Chavez MA; White AC
Expert Rev Anti Infect Ther; 2018 Aug; 16(8):655-661. PubMed ID: 30003818
[TBL] [Abstract][Full Text] [Related]
8. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa.
Doumbo O; Rossignol JF; Pichard E; Traore HA; Dembele TM; Diakite M; Traore F; Diallo DA
Am J Trop Med Hyg; 1997 Jun; 56(6):637-9. PubMed ID: 9230795
[TBL] [Abstract][Full Text] [Related]
9. A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box.
Jumani RS; Bessoff K; Love MS; Miller P; Stebbins EE; Teixeira JE; Campbell MA; Meyers MJ; Zambriski JA; Nunez V; Woods AK; McNamara CW; Huston CD
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339392
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial.
Nachipo P; Hermann D; Quinnan G; Gordon MA; Van Voorhis WC; Iroh Tam PY
Trials; 2018 Aug; 19(1):456. PubMed ID: 30139372
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in genetic manipulation of Cryptosporidium.
Vinayak S
Curr Opin Microbiol; 2020 Dec; 58():146-152. PubMed ID: 33161368
[TBL] [Abstract][Full Text] [Related]
12. Opportunities and Challenges in Developing a
Jumani RS; Blais J; Tillmann HC; Segal F; Wetty D; Ostermeier C; Nuber N; Lakshman J; Aziz N; Chandra R; Chen WH; Chappell CL; Diagana TT; Manjunatha UH
ACS Infect Dis; 2021 May; 7(5):959-968. PubMed ID: 33822577
[TBL] [Abstract][Full Text] [Related]
13. Treatment of human intestinal cryptosporidiosis: A review of published clinical trials.
Diptyanusa A; Sari IP
Int J Parasitol Drugs Drug Resist; 2021 Dec; 17():128-138. PubMed ID: 34562754
[TBL] [Abstract][Full Text] [Related]
14. Treatment and prevention of cryptosporidiosis: what options are there for a country like Zambia?
Kelly P
Parasitology; 2011 Oct; 138(12):1488-91. PubMed ID: 21320387
[TBL] [Abstract][Full Text] [Related]
15. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide.
Rossignol JF; Ayoub A; Ayers MS
J Infect Dis; 2001 Jul; 184(1):103-6. PubMed ID: 11398117
[TBL] [Abstract][Full Text] [Related]
16. Past, current, and potential treatments for cryptosporidiosis in humans and farm animals: A comprehensive review.
Khan SM; Witola WH
Front Cell Infect Microbiol; 2023; 13():1115522. PubMed ID: 36761902
[TBL] [Abstract][Full Text] [Related]
17. Prevention and treatment of cryptosporidiosis in immunocompromised patients.
Abubakar I; Aliyu SH; Arumugam C; Hunter PR; Usman NK
Cochrane Database Syst Rev; 2007 Jan; (1):CD004932. PubMed ID: 17253532
[TBL] [Abstract][Full Text] [Related]
18. Novel drug targets for treatment of cryptosporidiosis.
Wang B; Castellanos-Gonzalez A; White AC
Expert Opin Ther Targets; 2020 Sep; 24(9):915-922. PubMed ID: 32552166
[TBL] [Abstract][Full Text] [Related]
19. Emerging treatment options for cryptosporidiosis.
Love MS; Choy RKM
Curr Opin Infect Dis; 2021 Oct; 34(5):455-462. PubMed ID: 34261904
[TBL] [Abstract][Full Text] [Related]
20. Cryptic parasite revealed improved prospects for treatment and control of human cryptosporidiosis through advanced technologies.
Jex AR; Smith HV; Nolan MJ; Campbell BE; Young ND; Cantacessi C; Gasser RB
Adv Parasitol; 2011; 77():141-73. PubMed ID: 22137584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
